Literature DB >> 12533696

Virus complement evasion strategies.

Herman W Favoreel1, Gerlinde R Van de Walle1, Hans J Nauwynck1, Maurice B Pensaert1.   

Abstract

The immune system has a variety of tools at its disposal to combat virus infections. These can be subdivided roughly into two categories: 'first line defence', consisting of the non-specific, innate immune system, and 'adaptive immune response', acquired over time following virus infection or vaccination. During evolution, viruses have developed numerous, and often very ingenious, strategies to counteract efficient recognition of virions or virus-infected cells by both innate and adaptive immunity. This review will focus on the different strategies that viruses use to avoid recognition by one of the components of the immune system: the complement system. Complement evasion is of particular importance for viruses, since complement activation is a crucial component of innate immunity (alternative and mannan-binding lectin activation pathway) as well as of adaptive immunity (classical, antibody-dependent complement activation).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533696     DOI: 10.1099/vir.0.18709-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  43 in total

1.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

2.  Reciprocal antibody and complement responses of two chicken breeds to vaccine strains of Newcastle disease virus, infectious bursal disease virus and infectious bronchitis virus.

Authors:  R Baelmans; H K Parmentier; P Dorny; F Demey; D Berkvens
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

3.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 4.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

5.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 6.  Alphaherpesviruses and chemokines: pas de deux not yet brought to perfection.

Authors:  Gerlinde R Van de Walle; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.

Authors:  Budhaditya Mazumdar; Hangeun Kim; Keith Meyer; Sandip K Bose; Adrian M Di Bisceglie; Ratna B Ray; Michael S Diamond; John P Atkinson; Ranjit Ray
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

8.  Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway.

Authors:  Rheba S Bonaparte; Pamela S Hair; Deepa Banthia; Dawn M Marshall; Kenji M Cunnion; Neel K Krishna
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 9.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

10.  The structure of OMCI, a novel lipocalin inhibitor of the complement system.

Authors:  Pietro Roversi; Olga Lissina; Steven Johnson; Nurfilza Ahmat; Guido C Paesen; Kerstin Ploss; Wilhelm Boland; Miles A Nunn; Susan M Lea
Journal:  J Mol Biol       Date:  2007-03-30       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.